08:00 , Mar 6, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing to produce genetically modified monkeys Primate studies suggest CRISPR could be used to develop genetically modified...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Cellectis, Precision BioSciences deal

The companies will cross-license their respective technologies to settle infringement suits filed by both companies related to engineered I-CreI meganuclease technology. Precision declined to comment, and Cellectis could not be reached. The history includes many...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Cellectis, Precision BioSciences genomics news

Precision filed suit in the U.S. District Court for the Eastern District of North Carolina alleging that Cellectis is infringing on U.S. Patent Nos. 8,143,016 and 8,143,015 through the making, using, selling or importing into...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

Cellectis, Precision BioSciences genomics news

Precision filed suit in the U.S. District Court for the Eastern District of North Carolina alleging that Cellectis is infringing on U.S. Patent No. 8,129,134 through the sale of meganucleases targeting the HIV-1 genome, the...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Cellectis, Precision BioSciences genomics news

Precision filed suit in the U.S. District Court for the Eastern District of North Carolina alleging that Cellectis is infringing on U.S. Patent No. 8,021,867 through the sale of meganucleases targeting the human RAG1 gene,...
07:00 , Jul 8, 2002 |  BC Week In Review  |  Company News

Exelixis other research news

Researchers published in Science a method to obtain stable mutants of a gene in zebrafish based on gene sequence information. As proof of concept, they showed that chemically mutagenized parental fish gave rise to F1...